Replies to post #136938 on Biotech Values

[wallstarb]

$185m for $30m a yr for 10 yrs at 10% discount rate

[DewDiligence]

My calculation is pre-tax (and was acknowledged as such in the initial post in this thread.) That’s the cleanest way to run the numbers insofar as MNTA’s tax-status has several moving parts irrespective of Lovenox.

When valuing MNTA of course, you also have to add the estimated NPV of them winning their patent case (hard calculation) and their pipeline.

The pipeline is a separate matter altogether—this exercise is about the NPV of Lovenox (on a pre-tax basis). However, the patent-infringement lawsuit figures into the arithmetic in a material was, independently of the possibility of a Court-ordered damage award or settlement: if the Court were to re-establish an injunction at some point, MNTA’s royalty stream would clearly become much more valuable.